Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy.
Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity by which it grows has been a major barrier to progress in finding effective therapies. Thus, the treatment that is the current standard of care for these patients is largely palliative, and few are cured; however, novel therapies and approaches are being studied in patients with anaplastic thyroid carcinoma and are delineated herein.
The University of Texas MD Anderson Cancer Center, Houston, TX mcabani@mdanderson.org.
Maria E
ME
Cabanillas
The University of Texas MD Anderson Cancer Center, Houston, TX.
Mark
M
Zafereo
The University of Texas MD Anderson Cancer Center, Houston, TX.
G Brandon
GB
Gunn
The University of Texas MD Anderson Cancer Center, Houston, TX.
Renata
R
Ferrarotto
D005820:Genetic Testing; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D065646:Thyroid Carcinoma, Anaplastic / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy*